{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:54:31Z","timestamp":1782996871487,"version":"3.54.5"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T00:00:00Z","timestamp":1699056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T00:00:00Z","timestamp":1699056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007514","name":"Universit\u00e0 di Pisa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007514","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple Myeloma remains incurable, and there is a need for therapies with novel mechanisms of action. Recently, B cell maturation antigen targeted therapy has demonstrated deep and durable responses in a largely treated population. However, the relapse rate of myeloma patients after anti-BCMA treatment strategies is increasing worldwide, and one of the most challenging issues for them is to choose the best therapy sequencing. After anti-BCMA treatment, retreatment with anti-BCMA drugs remains an option, but new targets are emerging strongly. One of them is G protein-coupled receptor, class C group 5 member D (GPRC5D), that due to the very promising data from the use of chimeric\u00a0antigen receptor T-cells (CAR-T) and bispecific antibodies (BsAb) seems to be the ideal candidate in the relay of myeloma treatment at relapse. In this literature review, we discuss data from treatment with the new drugs at relapse after anti-BCMA therapies, observing an undeniable benefit from the use of drugs directed against GPRC5D.<\/jats:p>","DOI":"10.1007\/s00262-023-03559-4","type":"journal-article","created":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T09:02:12Z","timestamp":1699088532000},"page":"3931-3937","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agents"],"prefix":"10.1007","volume":"72","author":[{"given":"Maria Livia","family":"Del Giudice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Buda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,4]]},"reference":[{"issue":"1","key":"3559_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"3559_CR2","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A et al (2019) Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia 33(9):2266\u20132275. https:\/\/doi.org\/10.1038\/s41375-019-0435-7","journal-title":"Leukemia"},{"issue":"5","key":"3559_CR3","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, Weisel K, De Stefano V et al (2022) LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia 36(5):1371\u20131376. https:\/\/doi.org\/10.1038\/s41375-022-01531-2","journal-title":"Leukemia"},{"issue":"11","key":"3559_CR4","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1093\/intimm\/10.11.1693","volume":"10","author":"C Madry","year":"1998","unstructured":"Madry C, Laabi Y, Callebaut I, Roussel J, Hatzoglou A, Le Coniat M et al (1998) The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily. Int Immunol 10(11):1693\u20131702","journal-title":"Int Immunol"},{"issue":"11","key":"3559_CR5","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1002\/j.1460-2075.1992.tb05482.x","volume":"11","author":"Y La\u00e2bi","year":"1992","unstructured":"La\u00e2bi Y, Gras MP, Carbonnel F et al (1992) A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma. EMBO J 11(11):3897\u20133904. https:\/\/doi.org\/10.1002\/j.1460-2075.1992.tb05482.x","journal-title":"EMBO J"},{"issue":"7","key":"3559_CR6","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/nar\/22.7.1147","volume":"22","author":"Y Laabi","year":"1994","unstructured":"Laabi Y, Gras MP, Brouet JC, Berger R, Larsen CJ, Tsapis A (1994) The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Res 22(7):1147\u20131154. https:\/\/doi.org\/10.1093\/nar\/22.7.1147","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"3559_CR7","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood.V100.4.1113.h81602001113_1113_1122","volume":"100","author":"K Tarte","year":"2002","unstructured":"Tarte K, De Vos J, Thykjaer T, Zhan F, Fiol G, Costes V et al (2002) Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood 100(4):1113\u20131122","journal-title":"Blood"},{"key":"3559_CR8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1182\/blood-2002-10-3161","volume":"102","author":"K Tarte","year":"2003","unstructured":"Tarte K, Zhan F, De Vos J, Klein B, Shaughnessy J (2003) Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood 102:592\u2013600","journal-title":"Blood"},{"issue":"1","key":"3559_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"BP O\u2019Connor","year":"2004","unstructured":"O\u2019Connor BP, Raman VS, Erickson LD et al (2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 199(1):91\u201398","journal-title":"J Exp Med"},{"key":"3559_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","volume":"21","author":"F Mackay","year":"2003","unstructured":"Mackay F, Schneider P, Rennert P, Browning J (2003) BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 21:231\u2013264. https:\/\/doi.org\/10.1146\/annurev.immunol.21.120601.141152","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"3559_CR11","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","volume":"103","author":"AJ Novak","year":"2004","unstructured":"Novak AJ, Darce JR, Arendt BK et al (2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103(2):689\u2013694. https:\/\/doi.org\/10.1182\/blood-2003-06-2043","journal-title":"Blood"},{"issue":"Supplement 1","key":"3559_CR12","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1182\/blood-2022-165762","volume":"140","author":"A Mammadzadeh","year":"2022","unstructured":"Mammadzadeh A, Fulei Peng F et al (2022) Outcomes of patients who are BCMA (B-cell maturation Antigen) directed therapy (BDT) exposed Vs BCMA na\u00efve in penta-relapsed refractory multiple myeloma (RRMM). Blood 140(Supplement 1):4277\u20134278. https:\/\/doi.org\/10.1182\/blood-2022-165762","journal-title":"Blood"},{"issue":"5","key":"3559_CR13","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.clml.2021.10.013","volume":"22","author":"LJ Costa","year":"2022","unstructured":"Costa LJ, Lin Y, Cornell RF, Martin T, Chhabra S et al (2022) Comparison of Cilta-cel, an Anti-BCMA CAR-T cell therapy, versus conventional treatment in patients with relapsed\/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 22(5):326\u2013335. https:\/\/doi.org\/10.1016\/j.clml.2021.10.013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3559_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-021-00507-2","volume":"11","author":"S Jagannath","year":"2021","unstructured":"Jagannath S, Lin Y, Goldschmidt H et al (2021) KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood Cancer J 11:116. https:\/\/doi.org\/10.1038\/s41408-021-00507-2","journal-title":"Blood Cancer J"},{"key":"3559_CR15","unstructured":"Martin N, Thompson E, Dell\u2019Aringa J et al (2020) Correlation of tumor BCMA expression with response and acquired resistance to idecabtagene vicleucel in the KarMMa study in relapsed and refractory multiple myeloma. In: Paper presented at the 25th congress of the European hematology association (EHA25 Virtual), 11\u201314 Jun 2020"},{"issue":"4","key":"3559_CR16","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","volume":"27","author":"MC Da Vi\u00e0","year":"2021","unstructured":"Da Vi\u00e0 MC, Dietrich O, Truger M et al (2021) Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple mye- loma. Nat Med 27(4):616\u2013619","journal-title":"Nat Med"},{"issue":"1","key":"3559_CR17","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur MK, Fulciniti M, Aktas Samur A et al (2021) Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun 12(1):868","journal-title":"Nat Commun"},{"issue":"4","key":"3559_CR18","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3324\/haematol.2020.266841","volume":"108","author":"X Zhou","year":"2023","unstructured":"Zhou X, Rasche L, Kort\u00fcm KM et al (2023) BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice. Haematologica 108(4):958\u2013968. https:\/\/doi.org\/10.3324\/haematol.2020.266841","journal-title":"Haematologica"},{"issue":"9","key":"3559_CR19","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, Leblay N et al (2023) Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med 29(9):2295\u20132306. https:\/\/doi.org\/10.1038\/s41591-023-02491-5","journal-title":"Nat Med"},{"issue":"1","key":"3559_CR20","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","volume":"6","author":"SA Laurent","year":"2015","unstructured":"Laurent SA, Hoffmann FS, Kuhn PH et al (2015) g-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun 6(1):7333","journal-title":"Nat Commun"},{"key":"3559_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.leukres.2019.04.008","volume":"81","author":"H Chen","year":"2019","unstructured":"Chen H, Li M, Xu N et al (2019) Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells. Leuk Res 81:62\u201366","journal-title":"Leuk Res"},{"issue":"6","key":"3559_CR22","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen AD, Garfall AL, Stadtmauer EA et al (2019) B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest 129(6):2210\u20132221","journal-title":"J Clin Invest"},{"issue":"suppl 1","key":"3559_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood-2020-137650","volume":"136","author":"N Leblay","year":"2020","unstructured":"Leblay N, Maity R, Barakat E et al (2020) Cite-seq profiling of T cells in multiple myeloma patients undergoing BCMA targeting CAR-T or Bites immuno- therapy. Blood 136(suppl 1):11\u201312","journal-title":"Blood"},{"issue":"Supplement 1","key":"3559_CR24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1182\/blood-2022-157767","volume":"140","author":"DE Lowther","year":"2022","unstructured":"Lowther DE, Houseman EA, Han G et al (2022) No evidence of BCMA expression loss or systemic immune impairment after treatment with the BCMA-targeted antibody-drug conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 trials of patients with relapsed\/refractory multiple myeloma (RRMM). Blood 140(Supplement 1):611\u2013613. https:\/\/doi.org\/10.1182\/blood-2022-157767","journal-title":"Blood"},{"issue":"3","key":"3559_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/s0167-4781(01)00197-x","volume":"1518","author":"H Br\u00e4uner-Osborne","year":"2001","unstructured":"Br\u00e4uner-Osborne H, Jensen AA, Sheppard PO, Brodin B, Krogsgaard-Larsen P, O\u2019Hara P (2001) Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D. Biochim Biophys Acta 1518(3):237\u2013248. https:\/\/doi.org\/10.1016\/s0167-4781(01)00197-x","journal-title":"Biochim Biophys Acta"},{"key":"3559_CR26","unstructured":"GPRC5D\u00a0G protein-coupled receptor class C g. up 5 member D [Homo sapiens\u00a0(human)]\u00a0Gene ID: 55507, updated on 21-Jun-2023. https:\/\/www.ncbi.nlm.nih.gov\/gene\/55507. Accessed from 2 Aug 2023"},{"issue":"3","key":"3559_CR27","doi-asserted-by":"publisher","first-page":"e0151118","DOI":"10.1371\/journal.pone.0151118","volume":"11","author":"Y Gao","year":"2016","unstructured":"Gao Y, Wang X, Yan H et al (2016) Comparative transcriptome analysis of fetal skin reveals key genes related to hair follicle morphogenesis in cashmere Goats. PLoS ONE 11(3):e0151118. https:\/\/doi.org\/10.1371\/journal.pone.0151118","journal-title":"PLoS ONE"},{"issue":"3","key":"3559_CR28","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","volume":"122","author":"S Inoue","year":"2004","unstructured":"Inoue S, Nambu T, Shimomura T (2004) The RAIG family member, GPRC5D, is associated with hard-keratinized structures. J Invest Dermatol 122(3):565\u2013573. https:\/\/doi.org\/10.1046\/j.0022-202X.2004.12628.x","journal-title":"J Invest Dermatol"},{"issue":"5","key":"3559_CR29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.5021\/ad.2017.29.5.597","volume":"29","author":"YJ Kim","year":"2017","unstructured":"Kim YJ, Yoon B, Han K, Park BC (2017) Comprehensive transcriptome profiling of balding and non-balding scalps in trichorhinophalangeal syndrome type I patient. Ann Dermatol 29(5):597\u2013601. https:\/\/doi.org\/10.5021\/ad.2017.29.5.597","journal-title":"Ann Dermatol"},{"issue":"9","key":"3559_CR30","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","volume":"42","author":"J Atamaniuk","year":"2012","unstructured":"Atamaniuk J, Gleiss A, Porpaczy E et al (2012) Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Invest 42(9):953\u2013960. https:\/\/doi.org\/10.1111\/j.1365-2362.2012.02679.x","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"3559_CR31","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1179\/1607845413Y.0000000079","volume":"18","author":"Y Cohen","year":"2013","unstructured":"Cohen Y, Gutwein O, Garach-Jehoshua O, Bar-Haim A, Kornberg A (2013) GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells. Hematology 18(6):348\u2013351. https:\/\/doi.org\/10.1179\/1607845413Y.0000000079","journal-title":"Hematology"},{"issue":"485","key":"3559_CR32","doi-asserted-by":"publisher","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","volume":"11","author":"EL Smith","year":"2019","unstructured":"Smith EL, Harrington K, Staehr M et al (2019) GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med 11(485):eaau7746. https:\/\/doi.org\/10.1126\/scitranslmed.aau7746","journal-title":"Sci Transl Med"},{"issue":"Suppl 2","key":"3559_CR33","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1016\/S2152-2650(21)02229-1","volume":"21","author":"R Goldsmith","year":"2021","unstructured":"Goldsmith R, Cornax I, Ma JY, Yao X, Peng P, Carreira V (2021) Normal human tissue expression of G protein-coupled receptor class C group 5 member D (GPRC5D), a promising novel target for multiple myeloma, is restricted to plasma cells and hard keratinized tissue. Clin Lymphoma Myeloma Leuk 21(Suppl 2):S91\u2013S91","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"3559_CR34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A et al (2020) Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol 21(2):207\u2013221. https:\/\/doi.org\/10.1016\/S1470-2045(19)30788-0","journal-title":"Lancet Oncol"},{"issue":"12","key":"3559_CR35","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41408-021-00592-3","volume":"11","author":"I Vaxman","year":"2021","unstructured":"Vaxman I, Abeykoon J, Dispenzieri A et al (2021) \u201cReal-life\u201d data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience. Blood Cancer J 11(12):196. https:\/\/doi.org\/10.1038\/s41408-021-00592-3","journal-title":"Blood Cancer J"},{"issue":"16_suppl","key":"3559_CR36","doi-asserted-by":"publisher","first-page":"8060","DOI":"10.1200\/JCO.2022.40.16_suppl.8060","volume":"40","author":"M Becnel","year":"2022","unstructured":"Becnel M, Ferreri CJ et al (2022) Retrospective, single-center, real-world experience of belantamab mafodotin in relapsed\/refractory multiple myeloma. J Clin Oncol 40(16_suppl):8060","journal-title":"J Clin Oncol"},{"issue":"7","key":"3559_CR37","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1182\/blood.2022017848","volume":"141","author":"O Van Oekelen","year":"2023","unstructured":"Van Oekelen O, Nath K, Mouhieddine TH et al (2023) Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy. Blood 141(7):756\u2013765. https:\/\/doi.org\/10.1182\/blood.2022017848","journal-title":"Blood"},{"issue":"Supplement 1","key":"3559_CR38","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1182\/blood-2022-160401","volume":"140","author":"KR Reyes","year":"2022","unstructured":"Reyes KR, Liu Y, Huang C et al (2022) Clinical outcomes and salvage therapies in patients with relapsed\/refractory multiple myeloma following progression on BCMA-Targeted CAR-T Therapy. Blood 140(Supplement 1):617\u2013619","journal-title":"Blood"},{"issue":"10","key":"3559_CR39","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1080\/10428194.2021.1913143","volume":"62","author":"P Rodriguez-Otero","year":"2021","unstructured":"Rodriguez-Otero P, Ayers D, Cope S et al (2021) Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma. Leuk Lymphoma 62(10):2482\u20132491. https:\/\/doi.org\/10.1080\/10428194.2021.1913143","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"3559_CR40","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1182\/bloodadvances.2021004176","volume":"5","author":"N Gazeau","year":"2021","unstructured":"Gazeau N, Beauvais D, Yakoub-Agha I, Mitra S, Campbell TB, Facon T, Manier S (2021) Effective anti-BCMA retreatment in multiple myeloma. Blood Adv 5(15):3016\u20133020. https:\/\/doi.org\/10.1182\/bloodadvances.2021004176","journal-title":"Blood Adv"},{"issue":"16","key":"3559_CR41","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1182\/bloodadvances.2019000466","volume":"3","author":"AD Cohen","year":"2019","unstructured":"Cohen AD, Garfall AL, Dogan A, Lacey SF et al (2019) Serial treatment of relapsed\/refractory multiple myeloma with different BCMA-targeting therapies. Blood Adv 3(16):2487\u20132490. https:\/\/doi.org\/10.1182\/bloodadvances.2019000466","journal-title":"Blood Adv"},{"key":"3559_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/01.HS9.0000843628.63947.e4","volume":"6","author":"C Touzeau","year":"2022","unstructured":"Touzeau C, Krishnan A, Moreau P et al (2022) Evaluating teclistamab in patients with relapsed\/refractory multiple myeloma following exposure to other B-cell maturation antigen (BCMA)-targeted agents. Hemasphere 6:85\u201386","journal-title":"Hemasphere"},{"issue":"Suppl","key":"3559_CR43","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1097\/01.HS9.0000846460.44039.3d","volume":"6","author":"A Dalovisio","year":"2022","unstructured":"Dalovisio A, Bahlis N, Raje N et al (2022) P897: updated results from the ongoing phase 1 study of Elranatamab, a BCMA targeted t-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma. Hemasphere. 6(Suppl):788\u2013789. https:\/\/doi.org\/10.1097\/01.HS9.0000846460.44039.3d","journal-title":"Hemasphere."},{"key":"3559_CR44","doi-asserted-by":"publisher","unstructured":"Raje N, Bahlis NJ, Costello C et al (2022) Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma. In: 64th American society of hematology annual meeting. Abstract 158. Blood 140 (Suppl1): 388\u2013390. https:\/\/doi.org\/10.1182\/blood-2022-166494","DOI":"10.1182\/blood-2022-166494"},{"issue":"8","key":"3559_CR45","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N et al (2021) Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 384(8):705\u2013716. https:\/\/doi.org\/10.1056\/NEJMoa2024850","journal-title":"N Engl J Med"},{"issue":"10297","key":"3559_CR46","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ et al (2021) Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398(10297):314\u2013324. https:\/\/doi.org\/10.1016\/S0140-6736(21)00933-8","journal-title":"Lancet"},{"issue":"Supp 1","key":"3559_CR47","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1182\/blood-2022-164884","volume":"140","author":"CJ Ferreri","year":"2022","unstructured":"Ferreri CJ, Hildebrandt M, Hashmi H et al (2022) Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed\/refractory multiple myeloma (RRMM) who have received a prior BCMA-targeted therapy: real world, multi-institutional experience. Blood 140(Supp 1):1856\u20131858. https:\/\/doi.org\/10.1182\/blood-2022-164884","journal-title":"Blood"},{"issue":"Supp 16","key":"3559_CR48","doi-asserted-by":"publisher","first-page":"8012","DOI":"10.1200\/JCO.2023.41.16_suppl.8012","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Patel KK, Lc P et al (2023) Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol 41(Supp 16):8012\u20138012. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8012","journal-title":"J Clin Oncol"},{"issue":"11","key":"3559_CR49","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Surbhi Sidana S, Peres LC et al (2023) Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J Clin Oncol 41(11):2087\u20132097","journal-title":"J Clin Oncol"},{"issue":"3","key":"3559_CR50","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.2022015526","volume":"141","author":"AD Cohen","year":"2023","unstructured":"Cohen AD, Mateos MV, Cohen YC et al (2023) Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood 141(3):219\u2013230. https:\/\/doi.org\/10.1182\/blood.2022015526","journal-title":"Blood"},{"issue":"13","key":"3559_CR51","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody S, Devlin SM, Landa J et al (2022) GPRC5D-targeted CAR T cells for myeloma. N Engl J Med 387(13):1196\u20131206. https:\/\/doi.org\/10.1056\/NEJMoa2209900","journal-title":"N Engl J Med"},{"key":"3559_CR52","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1182\/blood-2022-162395","volume":"140","author":"S Bal","year":"2022","unstructured":"Bal S et al (2022) Clinical activity of BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T cell therapy, in patients with relapsed and\/or refractory (R\/R) multiple myeloma (MM): first results from a phase 1, multicenter, open-label study. Blood 140:883\u2013885","journal-title":"Blood"},{"key":"3559_CR53","doi-asserted-by":"publisher","first-page":"8004","DOI":"10.1200\/JCO.2022.40.16_suppl.8004","volume":"40","author":"H Huang","year":"2022","unstructured":"Huang H et al (2022) Phase I open-label single arm study of GPRC5D CAR T-cells (OriCAR-017) in patients with relapsed\/refractory multiple myeloma (POLARIS). J Clin Oncol 40:8004\u20138004","journal-title":"J Clin Oncol"},{"issue":"24","key":"3559_CR54","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema M, Berdeja J et al (2022) Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 387(24):2232\u20132244","journal-title":"N Engl J Med"},{"key":"3559_CR55","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood-2022-157988","volume":"140","author":"C Carlo-Stella","year":"2022","unstructured":"Carlo-Stella C et al (2022) RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study. Blood 140:397\u2013399","journal-title":"Blood"},{"key":"3559_CR56","doi-asserted-by":"crossref","unstructured":"Minnema MC, Krishnan AY, Berdeja JG, et al (2022) Efficacy and safety of talquetamab, a G proteincoupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): updated results from MonumenTAL-1 [abstract]. J Clin Oncol 40(suppl 16). Abstract 8015","DOI":"10.1200\/JCO.2022.40.16_suppl.8015"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03559-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03559-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03559-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T03:05:57Z","timestamp":1701918357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03559-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,4]]},"references-count":56,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["3559"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03559-4","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,4]]},"assertion":[{"value":"21 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}